WallStreetZen

NYSE: PBH
Prestige Consumer Healthcare Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for PBH

Based on 1 analysts offering 12 month price targets for Prestige Consumer Healthcare Inc.
Min Forecast
$63.00+10.31%
Avg Forecast
$63.00+10.31%
Max Forecast
$63.00+10.31%

Should I buy or sell PBH stock?

Based on 1 analysts offering ratings for Prestige Consumer Healthcare Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

PBH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
DA Davidson
Top 2%
99
HoldMaintains$63.00+10.31%2021-11-15
Anonymous
DA Davidson
HoldMaintains$49.00-14.20%2021-05-10

1 of 1

Forecast return on equity

Is PBH forecast to generate an efficient return?
Company
14.57%
Industry
27.79%
Market
46.73%
PBH's Return on Equity is forecast to be low in 3 years (14.57%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is PBH forecast to generate an efficient return on assets?
Company
5.79%
Industry
10.95%
PBH is forecast to generate lower Return on Assets (5.79%) than the US Healthcare industry average (10.95%)
Forecast

PBH earnings per share forecast

What is PBH's earnings per share in the next 2 years based on estimates from 4 analysts?
Avg 1 year Forecast
$3.98+11.48%
Avg 2 year Forecast
$4.25+19.05%
PBH's earnings are forecast to grow at a rate of 9.11% per year, which is not exceptional
Forecast

PBH revenue forecast

What is PBH's revenue in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
$1.1B+3.57%
Avg 2 year Forecast
$1.1B+7.44%
PBH's revenue is forecast to grow at a rate of 3.65% per year, which is not exceptional
Forecast

PBH earnings growth forecast

How is PBH forecast to perform vs Healthcare companies and vs the US market?
Company
9.11%
Industry
22.78%
Market
17.66%
PBH's earnings are forecast to grow slower (9.11% per year) than the US Healthcare industry average (22.78%)
Forecast
PBH's earnings are forecast to grow slower (9.11% per year) than the US market average (17.66%)
Forecast
PBH's earnings are forecast to grow faster (9.11% per year) than the risk-free savings rate (1.4%)
Forecast

PBH revenue growth forecast

How is PBH forecast to perform vs Healthcare companies and vs the US market?
Company
3.65%
Industry
17.7%
Market
10.77%
PBH's revenues are forecast to grow slower (3.65% per year) than the US Healthcare industry average (17.7%)
Forecast
PBH's revenues are forecast to grow slower (3.65% per year) than the US market average (10.77%)
Forecast

Prestige Consumer Healthcare Stock Forecast FAQ

Is Prestige Consumer Healthcare Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 1 Wall Street analysts covering (NYSE: PBH) stock is to Hold PBH stock.

Out of 1 analysts, 0 (0%) are recommending PBH as a Strong Buy, 0 (0%) are recommending PBH as a Buy, 1 (100%) are recommending PBH as a Hold, 0 (0%) are recommending PBH as a Sell, and 0 (0%) are recommending PBH as a Strong Sell.

What is PBH's earnings growth forecast for 2022-2023?

(NYSE: PBH) Prestige Consumer Healthcare's forecast annual earnings growth rate of 9.11% is not forecast to beat the US Healthcare industry's average forecast earnings growth rate of 22.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.66%.

Prestige Consumer Healthcare's earnings in 2021 is $179,467,000.On average, 4 Wall Street analysts forecast PBH's earnings for 2022 to be $199,414,561, with the lowest PBH earnings forecast at $197,911,436, and the highest PBH earnings forecast at $200,416,644.

In 2023, PBH is forecast to generate $212,942,684 in earnings, with the lowest earnings forecast at $210,437,476 and the highest earnings forecast at $215,447,892.

What is PBH's revenue growth forecast for 2022-2023?

(NYSE: PBH) Prestige Consumer Healthcare's forecast annual revenue growth rate of 3.65% is not forecast to beat the US Healthcare industry's average forecast revenue growth rate of 17.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.77%.

Prestige Consumer Healthcare's revenue in 2021 is $1,021,955,000.On average, 3 Wall Street analysts forecast PBH's revenue for 2022 to be $53,031,947,544, with the lowest PBH revenue forecast at $52,859,889,855, and the highest PBH revenue forecast at $53,135,613,053.

In 2023, PBH is forecast to generate $55,012,615,132 in revenue, with the lowest revenue forecast at $54,503,306,336 and the highest revenue forecast at $55,931,024,403.

What is PBH's forecast return on assets (ROA) for 2022-2023?

(NYSE: PBH) forecast ROA is 5.79%, which is lower than the forecast US Healthcare industry average of 10.95%.

What is PBH's Price Target?

According to 1 Wall Street analysts that have issued a 1 year PBH price target, the average PBH price target is $63.00, with the highest PBH stock price forecast at $63.00 and the lowest PBH stock price forecast at $63.00.

On average, Wall Street analysts predict that Prestige Consumer Healthcare's share price could stay at $63.00 by Nov 15, 2022. The average Prestige Consumer Healthcare stock price prediction forecasts a potential downside of N/A from the current PBH share price of $57.11.

What is PBH's Earnings Per Share (EPS) forecast for 2022-2023?

(NYSE: PBH) Prestige Consumer Healthcare's current Earnings Per Share (EPS) is $3.57. On average, analysts forecast that PBH's EPS will be $3.98 for 2022, with the lowest EPS forecast at $3.95, and the highest EPS forecast at $4.00. In 2023, PBH's EPS is forecast to hit $4.25 (min: $4.20, max: $4.30).

What is PBH's forecast return on equity (ROE) for 2022-2023?

(NYSE: PBH) forecast ROE is 14.57%, which is considered weak.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.